Background: EIF3D and the eIF3 Complex

Eukaryotic initiation factor 3 (eIF3) is the largest and most complex of the eukaryotic translation initiation factors, comprising up to 13 subunits (eIF3a–eIF3m) in mammals. The eIF3 complex plays a central role in ribosome biogenesis and the initiation of cap-dependent translation by facilitating 43S pre-initiation complex assembly and mRNA recruitment.

EIF3D (eukaryotic translation initiation factor 3 subunit D) is a component of this multiprotein assembly. It has been reported to contribute to mRNA cap recognition in a subset of cellular mRNAs, functioning as an alternative cap-binding protein and thereby influencing selective translational regulation. EIF3D is implicated in the regulation of cell proliferation, stress responses, and has been associated with dysregulated translation in various disease contexts.

Recombinant Human EIF3D Protein (rp367156) is produced for research applications requiring defined, high-purity material to study eIF3 subunit interactions, translation initiation mechanisms, and related biological processes.

Materials and Equipment

Before beginning, ensure the following materials and equipment are available:

• Recombinant Human EIF3D Protein (rp367156, Aladdin Scientific)
• Appropriate reconstitution buffer (e.g., sterile PBS, pH 7.4, or manufacturer-recommended buffer — consult the specific Certificate of Analysis for guidance)
• Low-binding microcentrifuge tubes (1.5 mL)
• Micropipettes and calibrated tips
• Microcentrifuge capable of ≥10,000 × g
• Ice bucket and dry ice for temperature-sensitive handling
• −80°C freezer for long-term storage
• Protein quantification reagents (e.g., BCA or Bradford assay kit)
• SDS-PAGE equipment (for quality verification if required)

Step-by-Step Protocol: Reconstitution and Handling

Step 1 – Thawing. Remove the vial from −80°C storage and allow it to thaw slowly on ice (approximately 10–15 minutes). Do not thaw at room temperature or use a water bath, as rapid temperature changes may reduce protein activity.

Step 2 – Brief centrifugation. Briefly centrifuge the vial (2,000–5,000 × g, 30 seconds) to collect any material from the cap and walls before opening.

Step 3 – Reconstitution (if lyophilized). If the product is supplied in lyophilized form, reconstitute by adding the recommended volume of sterile reconstitution buffer gently along the inner wall of the vial. Allow the vial to stand for 5–10 minutes on ice, then gently swirl — do not vortex — to dissolve. Consult the Certificate of Analysis for the recommended buffer composition and volume specific to lot rp367156.

Step 4 – Protein quantification. Determine protein concentration using a BCA or Bradford assay with BSA as standard. Record the concentration for accurate downstream dosing.

Step 5 – Aliquoting. Divide the reconstituted protein into single-use aliquots in low-binding tubes to avoid repeated freeze-thaw cycles, which can cause aggregation and loss of biological activity.

Step 6 – Storage. Snap-freeze aliquots in liquid nitrogen or dry ice/ethanol bath and store at −80°C. For short-term use (within 1–2 weeks), aliquots may be stored at 4°C. Avoid exposure to frost-free freezers that cycle through temperature fluctuations.

Note: Always consult the lot-specific Certificate of Analysis (CoA) supplied with the product for any deviations from these general guidelines.

Downstream Applications

Recombinant Human EIF3D Protein (rp367156) is suitable for a range of in vitro and biochemical research applications, including but not limited to:

• Protein–protein interaction studies: Co-immunoprecipitation (Co-IP), pull-down assays, or surface plasmon resonance (SPR) to map EIF3D interactions within the eIF3 complex or with mRNA cap structures.
• Structural biology: Use as a component in cryo-EM or X-ray crystallography studies aimed at resolving eIF3 subunit architecture.
• In vitro translation assays: Supplementation into reconstituted translation systems to assess the contribution of EIF3D to translation initiation efficiency.
• Antibody validation: Use as a positive control antigen for Western blot, ELISA, or immunofluorescence assay development targeting EIF3D.
• Enzyme and binding kinetics: Quantitative binding studies to characterize affinity interactions between EIF3D and partner proteins or nucleic acids.

Optimize protein concentration and buffer conditions empirically for each specific application. Include appropriate positive and negative controls in all functional assays.

Troubleshooting

The following table outlines common issues encountered when working with recombinant proteins such as EIF3D and suggested remedial actions:

• Protein aggregation or precipitation: Ensure the reconstitution buffer is appropriate (check ionic strength and pH). Centrifuge the reconstituted solution at 10,000 × g for 10 minutes at 4°C to remove aggregates before use. Avoid vortexing.
• Low or undetectable activity: Verify that the protein has not undergone more than one freeze-thaw cycle. Confirm storage conditions were maintained at −80°C. Check that the assay buffer is compatible with EIF3D stability.
• Unexpected band size on SDS-PAGE: Confirm whether the analysis was performed under reducing or non-reducing conditions. Consult the CoA for the expected molecular weight and purity specifications for lot rp367156.
• Inconsistent quantification results: Ensure the BCA or Bradford assay standard curve is prepared freshly and that any reconstitution buffer components (e.g., detergents) do not interfere with the assay. Consider using a spectrophotometric A280 measurement as an alternative.

If issues persist, contact Aladdin Scientific technical support with the product lot number and a description of experimental conditions.